Loading the content... Loading depends on your connection speed!
|
Risk Factors of Jabbour et al for Outcome in a Patient with Ph+ Chronic Myeloid Leukemia (CML) in Chronic Phase Treated with Nilotinib After Imatinib |
MyLikes |
MyPaths |
In order to access the algorithms, please subscribe to a plan that fits your needs.